Kinezodianone R hydrochloride

Small molecule

LLaboratoires Thea

Kinezodianone R hydrochloride is one of 32 small molecule programs targeting Glaucoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GlaucomaActive, not recruiting

GlaucomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

182 competitors in Glaucoma

#DrugCompanyPhaseTrials

Lucentis

Roche

Phase 3

2 2

Namenda

AbbVie

Phase 3

2 3

Eylea

Avastin

2 5

Viagra

VViatris Specialty LLC

Phase 3

1 6

Tocopherol

MM.D. Anderson Cancer Center

Phase 3

1 7

LUMIGAN

AbbVie

Phase 3

1 8

TFC-003

KKukje Pharma

Phase 3

1 9

T2345

LLaboratoires Thea

Phase 3

1 10

Prostaglandin

LLaboratoires Thea

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glaucoma1 trial

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

Active, not recruiting·LLaboratoires Thea·Phase 1/2·NCT05389267·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Kinezodianone R hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Kinezodianone R hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Kinezodianone R hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Laboratoires Thea company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: LLaboratoires Thea

Kinezodianone R hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glaucoma1 trial

References

Drug Info

Quick Facts

Related News